ReviewJournal of mid-life health
Bisphosphonates and Periodontal Health: A Systematic Review in Postmenopausal Women.
Review in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal women are disproportionately affected by two prevalent chronic conditions: osteoporosis and periodontitis. Bisphosphonates (BPs) are synthetic compounds with a high affinity for bone, widely used for treating postmenopausal osteoporosis due to their ability to inhibit bone resorption, thereby increasing BMD and reducing fracture risk. This systematic review evaluates various bisphosphonate therapies in improving periodontal conditions in postmenopausal women. Fifteen studies involving 776 participants were included. These comprised randomized controlled trials (RCTs), one split-mouth RCT, and one single-group follow-up. BPs studied included zoledronic acid, alendronate, and risedronate, administered via IV, oral, or local delivery. Evaluated parameters included clinical (probing depth [PD], clinical attachment loss [CAL], plaque index [PI], gingival index [GI], bleeding on probing [BOP], sulcus bleeding index [SBI], etc.), radiographic (bone fill, density, height changes), and biochemical/microbiological (N-terminal telopeptide [NTx], bone-specific alkaline phosphatase, and bacterial counts). Most studies reported significant improvements in PD, CAL, and indices like PI, GI, and BOP. Xu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.